[8-K] Caris Life Sciences, Inc. Reports Material Event
Caris Life Sciences, Inc. filed a Form 8-K dated August 12, 2025 stating that the company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company expressly states the press release is furnished, not "filed," and therefore is not subject to Section 18 liabilities or automatically incorporated by reference in other filings except as expressly noted.
The report is signed by Luke Power, Senior Vice President, Chief Financial Officer and Chief Accounting Officer. The filing identifies the company鈥檚 common stock as trading under the symbol CAI on The Nasdaq Stock Market and indicates the registrant is an emerging growth company. For the actual financial figures, readers must consult the furnished press release in Exhibit 99.1.
Caris Life Sciences, Inc. ha depositato un Modulo 8-K datato 12 agosto 2025, comunicando che ha pubblicato un comunicato stampa relativo ai risultati finanziari per il trimestre terminato 30 giugno 2025. Il comunicato 猫 fornito come Allegato 99.1 e la documentazione include anche una pagina di copertina Inline XBRL come Allegato 104. La societ脿 precisa che il comunicato 猫 'fornito' e non 'depositato', pertanto non 猫 soggetto alle responsabilit脿 previste dalla Sezione 18 n茅 viene incorporato automaticamente per riferimento in altri documenti salvo diversa indicazione esplicita.
Il rapporto 猫 firmato da Luke Power, Vicepresidente senior, Direttore finanziario e Responsabile della contabilit脿. Il deposito indica che le azioni ordinarie della societ脿 sono negoziate con il simbolo CAI sul Nasdaq e che il registrante 猫 una 'emerging growth company'. Per i dati finanziari effettivi, i lettori devono consultare il comunicato fornito in Allegato 99.1.
Caris Life Sciences, Inc. present贸 un Formulario 8-K con fecha 12 de agosto de 2025 en el que anuncia la publicaci贸n de un comunicado de prensa con los resultados financieros del trimestre terminado el 30 de junio de 2025. El comunicado se aporta como Anexo 99.1 y la presentaci贸n incluye adem谩s una portada Inline XBRL como Anexo 104. La compa帽铆a aclara que el comunicado se 'aporta' y no se 'presenta' como documento 'filed', por lo que no est谩 sujeto a las responsabilidades de la Secci贸n 18 ni se incorpora autom谩ticamente por referencia en otros documentos salvo que se indique expresamente lo contrario.
El informe est谩 firmado por Luke Power, Vicepresidente Senior, Director Financiero y Director de Contabilidad. La presentaci贸n identifica las acciones ordinarias de la compa帽铆a cotizando con el s铆mbolo CAI en Nasdaq e indica que el registrante es una 'emerging growth company'. Para conocer las cifras financieras reales, los lectores deben consultar el comunicado aportado en el Anexo 99.1.
Caris Life Sciences, Inc.電� 2025雲� 8鞗� 12鞚检瀽 Form 8-K毳� 鞝滌稖頃橂┐靹� 雼轨偓臧� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴 鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 氚濏様鞀惦媹雼�. 頃措嫻 氤措弰鞛愲電� 歃濍箼氍� 99.1搿� 鞝滉车霅橂┌, 鞝滌稖 靹滊鞐愲姅 Inline XBRL 響滌 韼橃澊歆�臧� 歃濍箼氍� 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 氤措弰鞛愲臧� '鞝滌稖霅�(filed)' 瓴冹澊 鞎勲媹霛� '鞝滉车霅�(furnished)' 瓴冹瀯鞚� 氇呾嫓頃橃棳 靹轨厴 18鞐� 霐半ジ 毂呾瀯鞚� 雽�靸侅澊 鞎勲媹氅� 雼るジ 鞝滌稖 氍胳劀鞐� 鞛愲彊鞙茧 韽暔霅橃 鞎婋姅雼り碃 氚濏様鞀惦媹雼�.
氤搓碃靹滊姅 Luke Power 靾橃劃攵�靷灔 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO) 氚� 斓滉碃須岅硠毂呾瀯鞛�(CAO)臧� 靹滊獏頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 須岇偓鞚� 氤错喌欤缄皜 雮橃姢雼レ棎靹� 鞁臣 CAI搿� 瓯半灅霅橁碃 鞛堨溂氅� 霌彪鞚胳澊 'emerging growth company'鞛勳澊 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞁れ牅 鞛 靾橃箻電� 歃濍箼氍� 99.1鞚� 氤措弰鞛愲毳� 彀胳“頃挫暭 頃╇媹雼�.
Caris Life Sciences, Inc. a d茅pos茅 un formulaire 8-K dat茅 du 12 ao没t 2025 indiquant que la soci茅t茅 a publi茅 un communiqu茅 de presse annon莽ant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025. Le communiqu茅 est fourni en tant que Pi猫ce 99.1 et le dossier comprend 茅galement une page de couverture Inline XBRL en tant que Pi猫ce 104. La soci茅t茅 pr茅cise explicitement que le communiqu茅 est 'fourni' et non 'd茅pos茅', et n'est donc pas soumis aux responsabilit茅s pr茅vues par la Section 18 ni incorpor茅 automatiquement par renvoi dans d'autres documents, sauf indication expresse contraire.
Le rapport est sign茅 par Luke Power, vice鈥憄r茅sident principal, directeur financier et directeur de la comptabilit茅. Le d茅p么t indique que les actions ordinaires de la soci茅t茅 sont cot茅es sous le symbole CAI sur le Nasdaq et pr茅cise que le d茅clarant est une 'emerging growth company'. Pour les chiffres financiers r茅els, les lecteurs doivent consulter le communiqu茅 fourni en Pi猫ce 99.1.
Caris Life Sciences, Inc. hat ein Formular 8-K mit Datum vom 12. August 2025 eingereicht und mitgeteilt, dass das Unternehmen eine Pressemitteilung zu den Finanzergebnissen f眉r das am 30. Juni 2025 endende Quartal ver枚ffentlicht hat. Die Pressemitteilung wird als Anlage 99.1 bereitgestellt; die Einreichung enth盲lt zudem eine Inline-XBRL-Titelseite als Anlage 104. Das Unternehmen stellt ausdr眉cklich klar, dass die Pressemitteilung 'bereitgestellt' und nicht 'eingereicht' wurde, weshalb sie nicht den Haftungsregelungen gem盲脽 Section 18 unterliegt und nicht automatisch durch Verweis in anderen Einreichungen aufgenommen wird, sofern nicht ausdr眉cklich anders angegeben.
Der Bericht ist von Luke Power, Senior Vice President, Chief Financial Officer und Chief Accounting Officer, unterzeichnet. Die Einreichung gibt an, dass die Stammaktien des Unternehmens unter dem K眉rzel CAI an der Nasdaq gehandelt werden und dass der Registrant eine 'emerging growth company' ist. F眉r die tats盲chlichen Finanzzahlen m眉ssen Leser die als Anlage 99.1 beigef眉gte Pressemitteilung konsultieren.
- Press release announcing Q2 2025 results was furnished as Exhibit 99.1, providing timely disclosure to the market.
- Inline XBRL cover page included as Exhibit 104, indicating structured data support for interactive review.
- The press release is furnished, not filed, which the company states limits Section 18 liability.
- The 8-K does not include the actual financial figures
Insights
TL;DR: Routine earnings disclosure furnished; 8-K contains no financial detail itself, directing investors to Exhibit 99.1 for Q2 results.
The filing notifies investors that a press release announcing results for the quarter ended June 30, 2025 was issued and furnished as Exhibit 99.1, with an Inline XBRL cover page included as Exhibit 104. The company clarifies the release is furnished rather than filed, limiting Section 18 liability. This is a standard operational disclosure that preserves formal reporting rights while providing timely access to results via the press release.
TL;DR: Disclosure complies with Form 8-K presentation norms; furnished status reduces filing liability and signature by CFO confirms proper authorization.
The document follows routine 8-K practice by furnishing the earnings press release (Exhibit 99.1) and including Inline XBRL data (Exhibit 104). The explicit statement that the release is furnished, not filed, is a legal distinction that limits Section 18 liability and potential incorporation by reference. The report is executed by the company鈥檚 CFO, indicating corporate authorization of the disclosure. No substantive financial metrics are included in the 8-K itself.
Caris Life Sciences, Inc. ha depositato un Modulo 8-K datato 12 agosto 2025, comunicando che ha pubblicato un comunicato stampa relativo ai risultati finanziari per il trimestre terminato 30 giugno 2025. Il comunicato 猫 fornito come Allegato 99.1 e la documentazione include anche una pagina di copertina Inline XBRL come Allegato 104. La societ脿 precisa che il comunicato 猫 'fornito' e non 'depositato', pertanto non 猫 soggetto alle responsabilit脿 previste dalla Sezione 18 n茅 viene incorporato automaticamente per riferimento in altri documenti salvo diversa indicazione esplicita.
Il rapporto 猫 firmato da Luke Power, Vicepresidente senior, Direttore finanziario e Responsabile della contabilit脿. Il deposito indica che le azioni ordinarie della societ脿 sono negoziate con il simbolo CAI sul Nasdaq e che il registrante 猫 una 'emerging growth company'. Per i dati finanziari effettivi, i lettori devono consultare il comunicato fornito in Allegato 99.1.
Caris Life Sciences, Inc. present贸 un Formulario 8-K con fecha 12 de agosto de 2025 en el que anuncia la publicaci贸n de un comunicado de prensa con los resultados financieros del trimestre terminado el 30 de junio de 2025. El comunicado se aporta como Anexo 99.1 y la presentaci贸n incluye adem谩s una portada Inline XBRL como Anexo 104. La compa帽铆a aclara que el comunicado se 'aporta' y no se 'presenta' como documento 'filed', por lo que no est谩 sujeto a las responsabilidades de la Secci贸n 18 ni se incorpora autom谩ticamente por referencia en otros documentos salvo que se indique expresamente lo contrario.
El informe est谩 firmado por Luke Power, Vicepresidente Senior, Director Financiero y Director de Contabilidad. La presentaci贸n identifica las acciones ordinarias de la compa帽铆a cotizando con el s铆mbolo CAI en Nasdaq e indica que el registrante es una 'emerging growth company'. Para conocer las cifras financieras reales, los lectores deben consultar el comunicado aportado en el Anexo 99.1.
Caris Life Sciences, Inc.電� 2025雲� 8鞗� 12鞚检瀽 Form 8-K毳� 鞝滌稖頃橂┐靹� 雼轨偓臧� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴 鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 氚濏様鞀惦媹雼�. 頃措嫻 氤措弰鞛愲電� 歃濍箼氍� 99.1搿� 鞝滉车霅橂┌, 鞝滌稖 靹滊鞐愲姅 Inline XBRL 響滌 韼橃澊歆�臧� 歃濍箼氍� 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 氤措弰鞛愲臧� '鞝滌稖霅�(filed)' 瓴冹澊 鞎勲媹霛� '鞝滉车霅�(furnished)' 瓴冹瀯鞚� 氇呾嫓頃橃棳 靹轨厴 18鞐� 霐半ジ 毂呾瀯鞚� 雽�靸侅澊 鞎勲媹氅� 雼るジ 鞝滌稖 氍胳劀鞐� 鞛愲彊鞙茧 韽暔霅橃 鞎婋姅雼り碃 氚濏様鞀惦媹雼�.
氤搓碃靹滊姅 Luke Power 靾橃劃攵�靷灔 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO) 氚� 斓滉碃須岅硠毂呾瀯鞛�(CAO)臧� 靹滊獏頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 須岇偓鞚� 氤错喌欤缄皜 雮橃姢雼レ棎靹� 鞁臣 CAI搿� 瓯半灅霅橁碃 鞛堨溂氅� 霌彪鞚胳澊 'emerging growth company'鞛勳澊 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞁れ牅 鞛 靾橃箻電� 歃濍箼氍� 99.1鞚� 氤措弰鞛愲毳� 彀胳“頃挫暭 頃╇媹雼�.
Caris Life Sciences, Inc. a d茅pos茅 un formulaire 8-K dat茅 du 12 ao没t 2025 indiquant que la soci茅t茅 a publi茅 un communiqu茅 de presse annon莽ant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025. Le communiqu茅 est fourni en tant que Pi猫ce 99.1 et le dossier comprend 茅galement une page de couverture Inline XBRL en tant que Pi猫ce 104. La soci茅t茅 pr茅cise explicitement que le communiqu茅 est 'fourni' et non 'd茅pos茅', et n'est donc pas soumis aux responsabilit茅s pr茅vues par la Section 18 ni incorpor茅 automatiquement par renvoi dans d'autres documents, sauf indication expresse contraire.
Le rapport est sign茅 par Luke Power, vice鈥憄r茅sident principal, directeur financier et directeur de la comptabilit茅. Le d茅p么t indique que les actions ordinaires de la soci茅t茅 sont cot茅es sous le symbole CAI sur le Nasdaq et pr茅cise que le d茅clarant est une 'emerging growth company'. Pour les chiffres financiers r茅els, les lecteurs doivent consulter le communiqu茅 fourni en Pi猫ce 99.1.
Caris Life Sciences, Inc. hat ein Formular 8-K mit Datum vom 12. August 2025 eingereicht und mitgeteilt, dass das Unternehmen eine Pressemitteilung zu den Finanzergebnissen f眉r das am 30. Juni 2025 endende Quartal ver枚ffentlicht hat. Die Pressemitteilung wird als Anlage 99.1 bereitgestellt; die Einreichung enth盲lt zudem eine Inline-XBRL-Titelseite als Anlage 104. Das Unternehmen stellt ausdr眉cklich klar, dass die Pressemitteilung 'bereitgestellt' und nicht 'eingereicht' wurde, weshalb sie nicht den Haftungsregelungen gem盲脽 Section 18 unterliegt und nicht automatisch durch Verweis in anderen Einreichungen aufgenommen wird, sofern nicht ausdr眉cklich anders angegeben.
Der Bericht ist von Luke Power, Senior Vice President, Chief Financial Officer und Chief Accounting Officer, unterzeichnet. Die Einreichung gibt an, dass die Stammaktien des Unternehmens unter dem K眉rzel CAI an der Nasdaq gehandelt werden und dass der Registrant eine 'emerging growth company' ist. F眉r die tats盲chlichen Finanzzahlen m眉ssen Leser die als Anlage 99.1 beigef眉gte Pressemitteilung konsultieren.
FAQ
What did Caris Life Sciences (CAI) disclose in this Form 8-K?
Caris Life Sciences disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025, furnished as Exhibit 99.1 to the Form 8-K.
Is the press release in the 8-K considered filed or furnished?
The press release is expressly furnished, not filed, and the company states it is therefore not subject to Section 18 liabilities or incorporated by reference except as expressly noted.
Which quarter do the results cover in the disclosed press release?
The press release covers the quarter ended June 30, 2025.
Where can I find the financial figures referenced by the 8-K?
The Form 8-K itself does not include financial figures; the detailed results are in the press release furnished as Exhibit 99.1.
Who signed the Form 8-K for Caris Life Sciences (CAI)?
Luke Power, Senior Vice President, Chief Financial Officer and Chief Accounting Officer, signed the Form 8-K dated August 12, 2025.
